[Skip to Content]
[Skip to Content Landing]
Other Articles
September 1, 1951


Author Affiliations

North Chicago, Ill.; Washington, D. C.

From the Department of Clinical Investigation, Abbott Laboratories (Dr. Tyler), and the Medical Division, Food and Drug Administration, Federal Security Agency (Dr. King).

JAMA. 1951;147(1):17-21. doi:10.1001/jama.1951.03670180023004

The purpose of this paper is to classify and tabulate the extensive clinical reports on the use of phenacemide (phenurone®) in the treatment of epileptic seizures, in order to attain a clearer picture of the uses and limitations of the drug which might otherwise not be available and to acquaint physicians with an anticonvulsant drug which, when used alone or in combination with other anticonvulsants, is capable of relieving certain patients of seizures which are not affected by other antiepileptic drugs known at present. Since this drug is not without toxic potentialities, physicians who use it should be thoroughly acquainted with the undesirable side effects which may occur and the precautions to be observed as well as with its efficacy.

This paper is not intended to discourage or interfere with subsequent publications by individual investigators. On the contrary, it is hoped that those who have had experience in the use

First Page Preview View Large
First page PDF preview
First page PDF preview